- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02812368
Clonidine for Sleep Disturbances in Children With Autism Spectrum Disorder
January 31, 2017 updated by: Jill Hollway, Ohio State University
Sleep disturbance has been reported in 44-86% of children with autism spectrum disorder (ASD) and is the source of considerable stress for the affected individual and family.
Sleep plays a role in development and learning processes; thus, the appropriate treatment of sleep disturbance is paramount to optimal outcomes.
The empirical base for treatments to address sleep in ASD is sparse, despite wide use of pharmacologic agents such as clonidine (CLN) to target sleep disturbance.
A randomized, controlled pilot investigation of CLN for sleep disturbance in children with ASD will allow investigators to evaluate the feasibility of conducting a much larger multisite trial to address the general lack of systematic data available to guide practitioners.
Subjects will be 16 children, ages 6-14 years, inclusive, with sleep disturbance and ASD.
This randomized double-blind, placebo-controlled (PBO), parallel groups study will test the efficacy of CLN following a brief sleep hygiene intervention.
Outcome measures include: informant completed sleep questionnaires, daytime behavior questionnaires, and actigraphy.
Biomarkers for medication response will include galvanic skin response and skin temperature.
Side effects will be monitored throughout the study.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Nisonger Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 14 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- outpatients between 6-14 years of age, inclusive, from underserved populations (i.e., Low SES, racial and ethnic minorities, rural populations);
- diagnosis of Autism Spectrum Disorder based on DSM-V criteria and the ATN assessment protocol;
- mental age ≥ 24 months as determined by the Stanford Binet-Fifth Edition (SB-5) or Mullen Scales of Early Learning (MSEL) (the child must be of a mental age to understand the BI/SH protocol);
significant sleep disturbance as determined the CSHQ 33-item Total Score of ≥ 48 and one of the following for the past four weeks by parent interview;
- ≥ 30 minutes delayed sleep onset, ≥ 3 times per week
- Sleep association problems, ≥ 3 nights per week, child falls asleep in a location other than his/her bed and requires parental intervention to return to his/her bed
- Nighttime Awakenings, ≥ 3 times per week, and child disturbs parent or enters into the parents' bedroom.
- Early Morning Awakenings, before 5 am ≥ 3 times per week and the child disturbs family members
- CGI Severity rating of ≥ 4 (Moderate) by the independent evaluator for sleep onset and/or sleep maintenance disruption at BL 2;
- care provider who can reliably bring subject to clinic visits and provide trustworthy ratings;
- stable dose of psychotropic medications (for at least 4 weeks with no plans to change over the course of the study);
- anticonvulsant if used for mood lability and it is working well;
- stable dose of exogenous melatonin for at least 4 weeks with no plans to change over the course of the study, as long as Phase II eligibility criteria are met prior to enrollment;
- sleep hygiene education responders who have relapsed and meet the Phase II study eligibility criteria
Exclusion Criteria:
- DSM-V diagnosis of bipolar disorder;
- subjects who are either melatonin naïve or who have not had an adequate trial of exogenous melatonin (defined as 3-5 mg for ≥ 4 weeks);
- seizure disorder/epilepsy;
- significant physical illness (e.g., serious cardiovascular, liver or renal pathology);
- medications specifically given for insomnia;
- pregnancy or sexually-active females without birth control;
- taking supplements or other complementary medical treatments where dose cannot be held at current level for duration of study;
- weight less than 15 kg;
- use of medicines for physical ailments that might interact with CLN or TRZ, such as guanfacine (Tenex, Intuniv), and propranolol (Inderol) or extended release clonidine (Kapvay);
- allergy to CLN or TRZ;
- Sleep Disordered Breathing (SDB) as defined by a total score of ≥ 3 on the CSHQ SDB subscale and parent report;
- prior adequate trial of CLN for sleep disturbance defined as at least 0.2mg q hs for 1 week;
- prior adequate trial of TRZ for sleep disturbance defined as ≥ 50 mg/day for 1 week;
- hyperthyroidism
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Clonidine
Taken once a day at bedtime; with the dose titrated from 0.05mg to 0.20mg over the course of 6 weeks
|
Other Names:
|
Placebo Comparator: Placebo (for clonidine)
Taken once a day at bedtime
|
Placebo pill manufactured to mimic clonidine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Children's Sleep Habits Questionnaire (CSHQ) Total Score
Time Frame: Change from Baseline to 6 Weeks
|
The primary outcome measure for this study is clinical improvement on the CSHQ (defined as a 30% or greater reduction in the Total Score of the 33 Sleep Items) at 6 weeks compared to baseline.
The CSHQ is the most commonly used parent-rated scale to assess sleep disturbance in pediatric populations.
It includes 33 items and is rated retrospectively over the previous week by parents to screen for the most common sleep problems.
The CSHQ incorporates items related to eight key sleep domains.
The eight subscales include: (1) bedtime resistance (2) sleep onset latency, (3) sleep duration, (4) anxiety around sleep, (5) night awakenings, (6) sleep disordered breathing, (7) parasomnias and (8) morning waking/daytime sleepiness.
A Total Score of 41 or greater on the CSHQ 33 items has been reported to be an appropriate clinical cut-off for identifying sleep problems in children.
|
Change from Baseline to 6 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2016
Primary Completion (Actual)
January 1, 2017
Study Completion (Actual)
January 1, 2017
Study Registration Dates
First Submitted
June 14, 2016
First Submitted That Met QC Criteria
June 23, 2016
First Posted (Estimate)
June 24, 2016
Study Record Updates
Last Update Posted (Estimate)
February 2, 2017
Last Update Submitted That Met QC Criteria
January 31, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Neurodevelopmental Disorders
- Child Development Disorders, Pervasive
- Autism Spectrum Disorder
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Sympatholytics
- Clonidine
Other Study ID Numbers
- 2016H0181
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism Spectrum Disorder
-
Stanford UniversityCalifornia Department of Developmental ServicesRecruitingAutism Spectrum Disorder | Autistic Disorder | Autism | Autism Spectrum Disorders | Autistic Disorders Spectrum | Autistic Spectrum Disorder | Autistic Spectrum DisordersUnited States
-
Hoffmann-La RocheActive, not recruitingAutism Spectrum Disorder (ASD)United States, Canada, Italy, Spain
-
Axial Therapeutics, Inc.Active, not recruitingAutism Spectrum Disorder (ASD)United States, Australia, New Zealand
-
Technion, Israel Institute of TechnologyCompleted
-
Stanford UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedAutism | Autism Spectrum Disorder (ASD)United States
-
Corporacion Parc TauliUnknown
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyTerminatedAutism Spectrum Disorder (ASD)Spain, United States, Hungary, Poland, Australia, United Kingdom, Brazil, Czechia, France, Italy, Portugal, Slovakia
-
Florida Gulf Coast UniversityCompletedAutism Spectrum Disorder High-FunctioningUnited States
-
Hospital Universitario Dr. Jose E. GonzalezUnknownAutism | Autism SpectrumMexico
-
National Taiwan University HospitalCompletedAutism Spectrum Disorder High-FunctioningTaiwan
Clinical Trials on Clonidine
-
BioDelivery Sciences InternationalCompletedNeuropathy | Painful Diabetic Neuropathy | Diabetic NeuropathyUnited States
-
OnxeoSimbec ResearchCompletedHealthyUnited Kingdom
-
Salem Anaesthesia Pain ClinicCompletedPain, Chronic | Insomnia ChronicCanada
-
Uwakwe Emmanuel ChijiokeRecruiting
-
Fred Hutchinson Cancer CenterInstitute for the Development of AfricaCompletedHIV Infections | HIV-1 and HSV-2 CoinfectionCameroon
-
Yung Shin Pharm. Ind. Co., Ltd.Completed
-
Afshan B. Hameed, M.D.Withdrawn
-
OnxeoCompletedOral MucositisSpain, United States, France, Germany, Hungary, Switzerland
-
Addrenex Pharmaceuticals, Inc.CompletedAttention Deficit Disorder With HyperactivityUnited States
-
The University of Texas Health Science Center,...CompletedWithdrawal; Therapeutic SubstanceUnited States